Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies.

CED Clinical Relevance  #89High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications.
🔬 Evidence Watch  |  CED Clinic
Alcohol Use DisorderCbdAddictionSystematic ReviewEndocannabinoid System
Journal Molecular psychiatry
Study Type Systematic Review
Population Human participants
Why This Matters

This comprehensive systematic review provides the most rigorous evidence synthesis to date on targeting the endocannabinoid system for alcohol use disorder treatment. With limited FDA-approved options for AUD and promising preclinical data on cannabis compounds, this analysis helps clarify which endocannabinoid interventions show therapeutic potential.

Clinical Summary

This systematic review and meta-analysis examined 63 preclinical and human studies evaluating endocannabinoid system modulators for alcohol use disorder. Preclinical meta-analyses demonstrated that CB-1 receptor inverse agonists significantly reduced alcohol intake (SMD = -1.21), as did CBD (SMD = -0.70), while CB-1 agonists increased consumption (SMD = +0.66). Dose-response analyses revealed non-linear effects for both CB-1 inverse agonists and CBD. Human studies showed methodological heterogeneity that precluded meta-analysis, highlighting the early stage of clinical research in this area.

Dr. Caplan’s Take

“While these preclinical findings are compelling, I remain cautious about extrapolating to clinical practice given the limited and heterogeneous human data. The mechanisms are biologically plausible, but we need well-designed human trials before considering endocannabinoid modulators as evidence-based AUD treatments.”

Clinical Perspective
🧠 Clinicians should view this as promising foundational research rather than practice-changing evidence. Patients with AUD asking about cannabis interventions should understand that while preclinical data suggests potential benefit from CBD and harm from THC-dominant products, robust human clinical trials are still needed to establish safety and efficacy.

💬 Join the Conversation

Have a question about how this applies to your situation? Ask Dr. Caplan →

Want to discuss this topic with other patients and caregivers? Join the forum discussion →

FAQ

This study item was assembled from normalized source metadata and pipeline scoring.






{“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies.”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41760917/”, “about”: “molecular psychiatry systematic review modulating endocannabinoid”, “isPartOf”: “Molecular psychiatry”}


,